Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID | D0FP0R | ||||
| Former ID | DCL000437 | ||||
| Drug Name | Apaziquone | ||||
| Synonyms | Apaziquonum; EOquin; Neoquin; E 09; EO 9; EO9; Apaziquone [USAN:INN]; Apaziquonum [INN-Latin]; E-09; EO 9 (pharmaceutical); EO-9; Eoquin (TN); NOR-701; Apaziquone (USAN/INN); E-85/050; E-85/053; (E)-5-(1-Azirinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione; 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)prop-beta-en-alpha-ol; 5-(Azridin-1-yl)-3-(hydroxymethyl)-2-((1E)-3-hydroxyprop-1-enyl)-methyl-1H-indole-4,7-dione; 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione | ||||
| Drug Type | Small molecular drug | ||||
| Indication | Non-invasive bladder cancer [ICD9: 188; ICD10:C67] | Phase 3 | [544745] | ||
| Company | Spectrum | ||||
| Formula | C15H16N2O4 | ||||
| Canonical SMILES | CN1C(=C(C2=C1C(=O)C=C(C2=O)N3CC3)CO)C=CCO | ||||
| InChI | 1S/C15H16N2O4/c1-16-10(3-2-6-18)9(8-19)13-14(16)12(20)7-11(15(13)21)17-4-5-17/h2-3,7,18-19H,4-6,8H2,1H3/b3-2+ | ||||
| InChIKey | MXPOCMVWFLDDLZ-NSCUHMNNSA-N | ||||
| CAS Number | CAS 114560-48-4 | ||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Human DNA | Target Info | Modulator | ||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.
